



1624
Atty. Dkt. No. 040283/0183

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#21A
ps

Applicant: Sarkis Barret KALINDJIAN *et al.*

Title: Histamine H₃ Receptor Ligands

Appl. No.: 09/622,544

Filing Date: October 13, 2000

Examiner: B. Kifle

Art Unit: 1624

RECEIVED
JUL 2 - 2003
TECH CENTER 1600/2900

AMENDMENT AND REPLY UNDER 37 C.F.R. §1.111

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

This Paper is filed in reply to the *non-final* Office Action mailed on April 23, 2003, for the above-referenced application. This paper is timely filed, *i.e.*, before the end of the shortened statutory period ending on July 23, 2003.

The amendments presented below comply with the revised amendment format permitted by the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office, dated February 10, 2003. Thus, the provisions of 37 C.F.R. § 1.121(a), (b), (c), and (d) are waived for amendments made to the claims, specification and drawings of this application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this document.

Remarks/Arguments begin on page 4 of this document.